A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma

NCT04559230 Phase 2 RECRUITING

This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.

Details

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	Phase 2
Status	RECRUITING
Enrolment	32
Start date	2022-01-06
Completion	2028-02

Conditions

• Recurrent Glioblastoma

Interventions

• Sacituzumab Govitecan

Primary outcomes

• Overall survival (OS) — 6 months
  Overall survival at 6 months including participants whose disease state has progressed

Countries

United States